Glenn P. Sblendorio

Glenn P. Sblendorio served as CEO and a member of the board of directors of Iveric Bio, from July 2017 until it was acquired by Astellas Pharma in July of 2023. Prior to Iveric, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and was a member of the board of directors of The Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also served as Chief Executive Officer, Managing Director and Senior Advisor of MPM Capital Advisors from 1996 through 2000. His prior experience also includes Senior Vice President and Chief Financial Officer of Sony Computer Entertainment and twelve years at Roche both in the US and Europe in a variety of senior financial roles.

Mr. Sblendorio has served as a member of the board of directors of Intercept Pharmaceuticals, Inc. He is currently a member of the board of directors at Amicus Therapeutics, Inc. He is also Chairman of Mineralys Therapeutics and Nanoscope Therapeutics and a member of the board at RentiNova. Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program.